Clinical Scorecard: Cotard’s delusion in a patient with schizophrenia
At a Glance
| Category | Detail |
|---|---|
| Condition | Cotard’s delusion, a rare neuropsychiatric phenomenon involving beliefs of being dead or no longer existing |
| Key Mechanisms | The case report describes nihilistic delusions in a patient with schizophrenia; it does not establish a mechanism. |
| Target Population | A man in his 40s with schizophrenia, medication nonadherence, and a history of substance use |
| Care Setting | Inpatient psychiatric care described in a single case report |
Key Highlights
- The patient presented with migraine and joint pain and reported believing he was dead, no longer existed, and had his throat cut.
- His drug screen was negative, and he had discontinued psychiatric medications.
- Oral risperidone was increased from 1 mg nightly to 2 mg twice daily; delusions had decreased by day 4, although paranoia and disorganized thinking persisted.
- He received 234 mg of long-acting injectable paliperidone palmitate on day 5 to address medication nonadherence; by day 6, the belief that he was dead had nearly resolved, leaving minor somatic complaints.
- Electroconvulsive therapy was not needed; sustained remission could not be confirmed because follow-up was unavailable.
Guideline-Based Recommendations
Diagnosis
- The case describes symptoms consistent with Cotard’s delusion; no diagnostic criteria or workup recommendations are provided.
Management
- In this case, clinicians initiated oral risperidone and later administered long-acting injectable paliperidone palmitate to address medication nonadherence.
- Electroconvulsive therapy was not required in this case.
Monitoring & Follow-up
- The report notes that sustained remission could not be confirmed because follow-up was unavailable.
Risks
- The patient had discontinued psychiatric medications; the report does not provide broader risk estimates or safety guidance.
Patient & Prescribing Data
One man in his 40s with schizophrenia, a history of substance use, and a negative drug screen.
Risperidone was started at 1 mg orally nightly and increased to 2 mg twice daily. On day 5, the patient received 234 mg of long-acting injectable paliperidone palmitate. His nihilistic delusion had nearly resolved by day 6.
Clinical Best Practices
- The case report describes assessing the patient’s reported beliefs alongside his psychiatric history, medication discontinuation, and drug-screen result.
- The report describes use of an injectable antipsychotic in this case to address medication nonadherence.
- The report does not establish long-term treatment outcomes because follow-up was unavailable.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
